Efficacy and Effectiveness of an rVSV-Vectored Vaccine Expressing Ebola Surface Glycoprotein: Interim Results from the Guinea Ring Vaccination Cluster-Randomised Trial
- Henao-Restrepo, A M
- Longini, I M
- Egger, M
- Dean, N E
- Edmunds, W J
- Camacho, A
- Carroll, M W
- Doumbia, M
- Draguez, B
- Duraffour, S
- Enwere, G
- Grais, R
- Gunther, S
- Hossmann, S
- Kondé, M K
- Kone, S
- Kuisma, E
- Levine, M M
- Mandal, S
- Norheim, G
- Riveros, X
- Soumah, A
- Trelle, S
- Vicari, A S
- Watson, C H
- Kéïta, S
- Kieny, M P
- Røttingen, J-A
Publication date
August 2015
DOI Publisher
Elsevier ISSN
0140-6736 Journal
1474-547xAbstract
A recombinant, replication-competent vesicular stomatitis virus-based vaccine expressing a surface glycoprotein of Zaire Ebolavirus (rVSV-ZEBOV) is a promising Ebola vaccine candidate. We report the results of an interim analysis of a trial of rVSV-ZEBOV in Guinea, west Africa
Add to ORKG